SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

June 22, 2015 07:00 ET

Dr. Elin Haf Davies Joins CTD Holdings' Family and Physicians Listening Circle on NPC Treatment

Dr. Davies Is an Expert in Metabolic Disorders, Development of Medications for Children and Has Been an Advisor to the EMA

ALACHUA, FL--(Marketwired - June 22, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, today announced that Dr. Elin Haf Davies of London, UK, will become a member of the company's Family and Physicians Listening Circle. This group serves as an information sharing forum for families, physicians, and CTD's International Clinical Program team working to develop the orphan drug designated Trappsol® Cyclo™ for the treatment of Niemann-Pick Type C (NPC), a rare and fatal disease found primarily in children.

Dr. Davies holds an MSc in Research Methods and a PhD in Neurometabolics focused on developing markers of neurological involvement in children with metabolic disorders. She is the author of many scientific papers and co-author of international clinical guidelines. She has worked as a scientific advisor for the European Medicine Agency, advising on the regulation of the development of drugs for children.

"I'm very honored to have been invited to join the Listening Circle," stated Dr. Davies, "I'm passionate about incorporating the views of children and their families in all the decision making processes that impact on their care, and see the Listening Circle as an opportunity to support that."

Dr. Davies joins Listening Circle Co-Chairs Sue French of the UK and Dr. Caroline Hastings of the US, and Listening Circle members David French, Dr. Robin Lachmann, both of the UK, and Dr. Begoña Arias of Madrid.

"Growing the Listening Circle expands CTD's opportunity to learn from the experiences of families and those providing care to NPC patients about potential trial design elements," said Dr. Sharon Hrynkow, a member of CTD's Scientific Advisory Board who was highly instrumental in forming the Listening Circle.

"We are delighted to include another colleague from Europe to the Listening Circle," Dr. Hrynkow added.

About the Company:
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in the research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann-Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information